A carregar...

Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials

BACKGROUND: Nearly all available treatments for pulmonary arterial hypertension have been approved based on change in 6-minute walk distance (Δ6MWD) as a clinically important end point, but its validity as a surrogate end point has never been shown. We aimed to validate the difference in Δ6MWD again...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Circulation
Main Authors: Gabler, Nicole B., French, Benjamin, Strom, Brian L., Palevsky, Harold I., Taichman, Darren B., Kawut, Steven M., Halpern, Scott D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4237273/
https://ncbi.nlm.nih.gov/pubmed/22696079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.112.105890
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!